Novartis’s Adakveo (crizanlizumab) Receives NICE Recommendation as a New Therapy for Sickle Cell Disease
Novartis Entered into a Collaboration and License Agreement with Dunad to Develop Oral Targeted Protein Degrader Therapies
Shots:
- The NICE has recommended Novartis’ Adakveo (crizanlizumab) as a new treatment option to prevent recurrent sickle cell crises in patients aged ≥16
- Additionally, patients will now have access to this treatment option on the NHS. The clinical evidence demonstrated that the people treated with crizanlizumab have significantly fewer sickle cell crises in a year compared to the other standard treatment options
- The recommendation was based on cost-effective treatment & the main objective of NICE is to reduce health inequalities. The therapy showed high uncertainty in the long-term & cost-effective treatment & will not be recommended for routine use on the NHS
Click here to read full press release/ article | Ref: NICE | Image: BioProcess International